Journal of Pharmacological Sciences, 2015 Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami +16 more
doaj +3 more sources
Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]
FASEB BioAdvancesPancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‐related mortality, characterized by intrinsic resistance to conventional therapies and limited effective treatment options. In this study, we investigated the role of the CXCR2
Caitlin Molczyk +8 more
doaj +2 more sources
Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer [PDF]
BiomoleculesOral microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) and may contribute to chemotherapy resistance. While previous studies attributed bacteria-induced resistance to indirect host modulation, recent findings suggest a direct ...
Geng Xu +8 more
doaj +2 more sources
Integrated transcriptomic analysis identifies lactylation-linked gemcitabine resistance and therapeutic targets in intrahepatic cholangiocarcinoma [PDF]
Frontiers in Cell and Developmental BiologyBackgroundIntrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy of the bile ducts, and resistance to gemcitabine, a first-line chemotherapy, significantly complicates treatment.
Wenwei Xie +5 more
doaj +2 more sources
The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability [PDF]
Cell Death and DiseaseGemcitabine resistance is a major clinical challenge in pancreatic cancer (PC); therefore, strategies to combat gemcitabine resistance are urgently required. Reprogramming pyrimidine metabolism by oncogenic signaling contributes to cancer progression and
Wenming Zhang +8 more
doaj +2 more sources
CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1 [PDF]
Advanced SciencePancreatic ductal adenocarcinoma (PDAC) is a fatal cancer with poor prognosis. COP9 signalosome subunit 6 (CSN6), a key regulator of different E3 ubiquitin ligases, plays oncogenic roles in various cancers.
Yijing Zhang +14 more
doaj +2 more sources
TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway [PDF]
Cell Death and DiseasePancreatic cancer (PC) is one of the most lethal malignant tumors that lacks effective treatment, and gemcitabine-based chemoresistance occurs frequently. Therefore, new therapeutic strategies for PC are urgently needed.
Shiyu Chen +8 more
doaj +2 more sources
Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]
Research in Oncology, 2021 Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei +4 more
doaj +1 more source
Cancer Biology & Medicine, 2023 Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu +19 more
doaj +1 more source
Molecular Cancer, 2022 Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu +12 more
doaj +1 more source